---
title: "Fosun Pharma: \"Compound Potassium Dihydrogen Phosphate Injection\" has obtained acceptance for its market approval application"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/202595335.md"
description: "Fusen Pharmaceutical's wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has submitted an application for the listing of \"Compound Potassium Dihydrogen Phosphate Injection\" and it has been accepted. This product is used to treat hypophosphatemia and patients requiring phosphorus supplementation for parenteral nutrition, with features such as high safety, rapid absorption, and dual phosphorus-potassium supplementation. The listing of this product will provide more treatment options for adults and children. Additionally, this product enriches Fusen Pharmaceutical's product pipeline in the field of nutritional supplements"
datetime: "2024-04-23T11:03:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/202595335.md)
  - [en](https://longbridge.com/en/news/202595335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/202595335.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/202595335.md) | [繁體中文](https://longbridge.com/zh-HK/news/202595335.md)


# Fosun Pharma: "Compound Potassium Dihydrogen Phosphate Injection" has obtained acceptance for its market approval application

According to the Zhitong Finance APP, Fosun Pharma (01652) announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Medical Technology Co., Ltd., has developed a "Compound Potassium Dihydrogen Phosphate Injection" which has been submitted for listing application to the China National Medical Products Administration and has been accepted. It is used for the treatment of the following diseases: as a supplement of phosphorus in total parenteral nutrition therapy; it can also be used for hypophosphatemia caused by certain diseases.

Phosphorus is involved in sugar metabolism through phosphorylation, constitutes phospholipids in membrane components, and is an important component of RNA, DNA, and many coenzymes in cells. Phosphorus also participates in energy storage conversion, transport, and regulation of body fluid buffering functions. The "Compound Potassium Dihydrogen Phosphate Injection" is a phosphorus supplement: used for intravenous infusion therapy in adult and pediatric patients with hypophosphatemia when oral or enteral supplementation is impossible, insufficient, or contraindicated; used for parenteral nutrition in adult and pediatric patients when oral or enteral nutrition is impossible, insufficient, or contraindicated.

This product is classified as a Category B medical insurance drug, a national essential drug, with characteristics such as high safety, rapid absorption and efficacy, dual supplementation of phosphorus and potassium, and consensus in multiple guidelines. The "Compound Potassium Dihydrogen Phosphate Injection" developed by our company is classified as a chemical drug Category 3 for application, with a prescription that is basically consistent with the reference original research preparation, and strict control of product quality to ensure that its quality is superior to or consistent with the reference original research preparation, ensuring patient medication safety. In addition, non-clinical safety studies are conducted as required by regulations, and the results show that the special safety of this product is consistent with the reference preparation. The "Compound Potassium Dihydrogen Phosphate Injection" provides a very favorable risk-benefit ratio in improving laboratory test results and clinical symptoms for adult and pediatric patients requiring phosphorus supplementation for the treatment of hypophosphatemia and parenteral nutrition.

Furthermore, the "Compound Potassium Dihydrogen Phosphate Injection" is another important product of the group, further enriching the group's product pipeline in the field of nutritional supplements. After the product is launched, it will provide more treatment options for adult and pediatric patients with hypophosphatemia and those requiring parenteral nutrition

### Related Stocks

- [FUSEN PHARM (01652.HK)](https://longbridge.com/en/quote/01652.HK.md)

## Related News & Research

- [CATL's controlling shareholder to donate some A-shares](https://longbridge.com/en/news/281197776.md)
- [Hansoh Pharmaceutical Group (SEHK:3692) Net Margin Strength Backs Bullish Narratives](https://longbridge.com/en/news/281032561.md)
- [Hua Hong Semiconductor Wins SSE Acceptance for Share-Issuance Acquisition Plan](https://longbridge.com/en/news/281182290.md)
- [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/en/news/281343251.md)
- [Rubio says Venezuela will ultimately need transition phase, free and fair elections](https://longbridge.com/en/news/281280690.md)